Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William D Figg

Showing results (11-20 of 637) with videos related to

Pageof 64
Sort By:
Idrugs : the Investigational Drugs Journal|October 4, 2006
Prostate cancer - 6th International CongressWilliam D Figg, Sandra Ockers
Anticancer Research|January 2, 2016
Using Epigenetic Therapy to Overcome Chemotherapy ResistanceJulius Strauss, William D Figg
Cancer Biology & Therapy|February 7, 2004
Upregulation of the androgen receptor during prostate cancer progressionArun Singh, William D Figg
Cancer Biology & Therapy|June 25, 2013
Monitor tumor burden with circulating tumor DNAWilliam D Figg, Jim Reid
The New England Journal of Medicine|May 3, 2002
Irinotecan in small-cell lung cancerYuichi Ando, William D Figg
Cancer Biology & Therapy|August 23, 2008
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistanceWeixin Wang, William D Figg
Cancer Biology & Therapy|May 21, 2014
New mechanism of lenalidomide activityJacob Keevan, William D Figg
Cancer Biology & Therapy|September 7, 2010
Androgen synthesis and steroid transporters in prostate cancer: rethinking the transition to CRPCHeather M Pressler, William D Figg
Cancer Biology & Therapy|October 14, 2009
Antiandrogens in the 21st centuryStephen T Pisle, William D Figg
Cell Cycle (Georgetown, Tex.)|May 22, 2004
hTert-immortalized endothelial cells: an important new research toolDouglas K Price, William D Figg
Pageof 64

Showing results (11-20 of 637) with videos related to

Sort By:
Pageof 64
Idrugs : the Investigational Drugs Journal|October 4, 2006
Prostate cancer - 6th International CongressWilliam D Figg, Sandra Ockers
Anticancer Research|January 2, 2016
Using Epigenetic Therapy to Overcome Chemotherapy ResistanceJulius Strauss, William D Figg
Cancer Biology & Therapy|February 7, 2004
Upregulation of the androgen receptor during prostate cancer progressionArun Singh, William D Figg
Cancer Biology & Therapy|June 25, 2013
Monitor tumor burden with circulating tumor DNAWilliam D Figg, Jim Reid
The New England Journal of Medicine|May 3, 2002
Irinotecan in small-cell lung cancerYuichi Ando, William D Figg
Cancer Biology & Therapy|August 23, 2008
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistanceWeixin Wang, William D Figg
Cancer Biology & Therapy|May 21, 2014
New mechanism of lenalidomide activityJacob Keevan, William D Figg
Cancer Biology & Therapy|September 7, 2010
Androgen synthesis and steroid transporters in prostate cancer: rethinking the transition to CRPCHeather M Pressler, William D Figg
Cancer Biology & Therapy|October 14, 2009
Antiandrogens in the 21st centuryStephen T Pisle, William D Figg
Cell Cycle (Georgetown, Tex.)|May 22, 2004
hTert-immortalized endothelial cells: an important new research toolDouglas K Price, William D Figg
Pageof 64